Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SII-YFV vs STAMARIL for Yellow Fever Prevention
NCT05421611Phase 3Completed
- Sponsor
- Serum Institute of India
- Start
- May 2023
- Primary completion
- May 2024
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of 17D yellow fever vaccine in yellow fever (2 arms), sponsored by Serum Institute of India. Primary endpoint: YF neutralizing antibody (NAb) seroconversion rates at 28 days. Started May 2023; status: completed.
02
Drugs
17D yellow fever vaccine
03
Conditions
yellow fever
Beyond the preview
Go deeper on NCT05421611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05421611.